To correlate the variable clinical features of oestrogen-receptor-positive breast cancer with
somatic alterations, we studied pretreatment tumour biopsies accrued from patients in two …

Purpose Current immunohistochemical (IHC)-based definitions of luminal A and B breast
cancers are imperfect when compared with multigene expression-based assays. In this …

Background In breast cancer, immunohistochemical assessment of proliferation using the
marker Ki67 has potential use in both research and clinical management. However, lack of …

Purpose Chemotherapy has been the historical mainstay of treatment for patients with breast
cancer, with immunohistochemical markers and tumor characteristics driving treatment …

Background In hormone receptor-positive, HER2-negative early stage breast cancer, cyclin-
dependent kinases 4 and 6 (CDK4/6) inhibition in combination with endocrine therapy could …

Biological changes that occur during metastatic progression of breast cancer are still
incompletely characterized. In this study, we compared intrinsic molecular subtypes and …

Estrogen receptor (ER) expression is the main indicator of potential responses to endocrine
therapy (ET), and approximately 70% of human breast cancers (BCs) are hormone …

Approximately 80% of breast cancers (BC) are estrogen receptor (ER)-positive and thus
endocrine therapy (ET) should be considered complementary to surgery in the majority of …

Author links open overlay panel F. Cardoso a, A. Costa bc, L. Norton d, E. Senkus e, M.
Aapro f, F. André g, CH Barrios h, J. Bergh i, L. Biganzoli j, KL Blackwell k, MJ Cardoso l, T …

Whole-genome analyses have revealed that muscle-invasive bladder cancers (MIBCs) are
heterogeneous and can be grouped into basal and luminal subtypes that are highly …